Skip to main content
Welcome to
Sanofi
About us
About us
U.S. LEADERSHIP
Our Stories
Corporate Compliance
Corporate Compliance
California Compliance Law
Shannon Kelley
California Compliance Law - Sanofi Pasteur
Compliance Program for Sanofi Pasteur
Committed to Transparency
Sanofi Websites in the U.S.
Your Health
Your Health
Vaccines
Science & Innovation
Science & Innovation
Clinical Trials
INVESTIGATOR SPONSORED STUDIES (ISS)
Products & Resources
Products & Resources
Prescription Products
Vaccines Products
Vaccines Products
Yellow Fever Vaccine Information
Generics
Consumer Health (OTC) Products
U.S. Patents
Patient Support Services
Resources for Healthcare Providers
Colorado Disclosure
Vermont Disclosure
Our Responsibility
Our Responsibility
Corporate Social Responsibility
Access to Healthcare
Patient Advocacy at Sanofi in the U.S.
Patient Advocacy at Sanofi in the U.S.
Health Equity at Sanofi in the U.S.
2023 Health Equity Accelerator Awards: Application Guidelines
2022 Health Equity Accelerator Award Winners
Health Equity Accelerator Awards Aim to Expand Solutions for Bigger Impact
Patient Centered Healthcare Value Assessment
Diversity, Equity & Inclusion
Diversity, Equity & Inclusion
A Million Conversations: Addressing Disparities in Healthcare
Diversity in Clinical Trials
Employee Resource Groups
Supplier Diversity
Contributions and Giving
Contributions and Giving
TORCH Awards
Sponsorships
Philanthropic Donations
Healthcare Contributions
Independent Medical Education (IME/CME) Grants
Fellowships
Rare Genetic Disease Fellowships
Patient Assistance Foundations
Pricing Principles
Pricing Principles
2023 Pricing Principles Report
Clear Rationale for Pricing
Limited U.S. Price Increases
Continued Transparency in the U.S.
Prioritizing Patient Affordability
Healthy Planet
Careers
Careers
Benefits
Diversity
Postdoctoral Careers
Physician Careers
Students
Veterans
Investors
Media
Toggle navigation
Media Room Menu
Home
Press Releases
Subscribe
Social Media
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Mar 8, 2024
New data presented at AAD showcase continued commitment to advance treatments for inflammatory dermatologic diseases
Feb 24, 2024
Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
Feb 23, 2024
Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Feb 9, 2024
New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases
Feb 5, 2024
Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Feb 1, 2024
Sanofi launches Beyfortus® (nirsevimab-alip) Reservation Program for 2024-2025 RSV season in U.S.
Jan 25, 2024
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Jan 16, 2024
Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement
Dec 14, 2023
Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Dec 13, 2023
Study: Sanofi Flublok® Quadrivalent (Influenza Vaccine) provides better protection against flu infection versus standard dose in adults ages 50-64
Dec 11, 2023
Sarclisa® (isatuximab-irfc) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Dec 7, 2023
Sarclisa® (isatuximab-irfc) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Nov 17, 2023
Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Nov 7, 2023
Sanofi to present clinical data reinforcing commitment to scientific innovation across blood cancers and rare blood disorders at ASH 2023
Nov 6, 2023
Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Nov 2, 2023
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
Nov 1, 2023
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
Oct 22, 2023
Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Oct 20, 2023
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
Oct 18, 2023
TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine
Oct 13, 2023
Sanofi Beyfortus™ (nirsevimab-alip) Statement
Oct 4, 2023
Phase 3 data demonstrating efficacy of Kevzara® (sarilumab) for patients with polymyalgia rheumatica published in NEJM
Sep 26, 2023
Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for Priority Review
Sep 13, 2023
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
Photos
4
Sep 12, 2023
ALTUVIIIO® supplemental biologics license application based on positive final results from Phase 3 XTEND-Kids study accepted by FDA
First-in-class ALTUVIIIO offers clinically proven highly effective bleed protection with once-weekly dosing for children with hemophilia A
Aug 24, 2023
Beyfortus™ (nirsevimab-alip) recommended for routine use to protect infants against RSV disease in CDC Morbidity and Mortality Weekly Report
The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
Aug 3, 2023
U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jul 25, 2023
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jun 25, 2023
ALTUVIIIO™ late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
Jun 8, 2023
FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
Jun 2, 2023
New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023
May 21, 2023
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 18, 2023
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
May 5, 2023
New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline
17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
May 1, 2023
Sanofi Canada et Diabetes Care Community annoncent une collaboration pour soutenir le parcours de bien-être émotionnel des Canadiens et Canadiennes vivant avec le diabète
Apr 27, 2023
Sanofi completes acquisition of Provention Bio, Inc.
Apr 4, 2023
Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
Mar 23, 2023
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
Mar 18, 2023
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
Mar 13, 2023
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Mar 7, 2023
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Mar 3, 2023
Provention Bio Announces the Grant of Inducement Awards
Mar 2, 2023
Sanofi launches R&D Consortium of industry and patient advocacy groups to accelerate medicines development
Feb 28, 2023
Kevzara® (sarilumab) approved by FDA as first and only biologic indicated for patients with polymyalgia rheumatica
Feb 24, 2023
New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa-ngpt) as potential new standard of care for all people living with late-onset Pompe disease
Feb 23, 2023
FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
Feb 23, 2023
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Feb 13, 2023
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Feb 8, 2023
Provention Bio to Present at the SVB Securities Global Biopharma Conference
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
23
»
Print
Email page
RSS